

## Module 2.7

### Clinical Summary

**THIOPECTOL THYM SANS SUCRE EDULCORE AU  
MALTITOL, 6.5 g/100 ml**

**Sirop**

## Table of Contents

<b>2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods .....</b>	<b>5</b>
2.7.1.1 Background and Overview .....	5
2.7.1.2 Summary of Results of Individual Studies .....	5
2.7.1.3 Comparison and Analyses of Results Across Studies.....	5
<b>2.7.2 Summary of Clinical Pharmacology Studies .....</b>	<b>6</b>
2.7.2.1 Background and Overview .....	6
2.7.2.2 Summary of Results of Individual Studies .....	7
2.7.2.3 Comparison and Analysis of Results Across Studies .....	7
2.7.2.4 Special Studies .....	10
<b>2.7.3 Summary of Clinical Efficacy .....</b>	<b>11</b>
2.7.3.1 Background and Overview of Clinical Efficacy .....	11
2.7.3.2 Summary of Results of Individual Studies .....	11
2.7.3.3 Analysis of Clinical Information Relevant to Dosing Recommendations .....	12
2.7.3.4 Appendix.....	13
<b>2.7.4 Summary of Clinical Safety.....</b>	<b>14</b>
2.7.4.1 Exposure to the Drug .....	14
2.7.4.2 Adverse Events .....	14
2.7.4.3 Clinical Laboratory Evaluations .....	15
2.7.4.4 Vital signs, Physical Findings and Other Observations Related to Safety .....	15
2.7.4.5 Safety in Special Groups and Situations.....	15
2.7.4.6 Post marketing data.....	16
<b>2.7.5 References.....</b>	<b>17</b>
<b>2.7.6 Synopses of Individual Studies.....</b>	<b>20</b>
2.7.6.1 Produktieve hoest: tijm of broomhexine? Een dubbelblind gerandomiseerd onderzoek [Productive cough: Thyme or bromhexine? A double-blind randomised investigation] Knols et al 1994.....	20
2.7.6.2 Company report cited in an ESCOP monograph .....	21

## List of Abbreviations

AUC	area under the concentration-time curve;
CL	clearance
C <sub>max</sub>	peak plasma concentration
CYP	cytochrome P450
DER	Drug Extract Ratio
EMA	European Medicines Agency
ESCOP	European Scientific Cooperative on Phytotherapy
MAT	mean absorption time
MRT	mean residence time
t <sub>1/2</sub>	elimination half-life
t <sub>max</sub>	time to reach C <sub>max</sub>
Vdss	volume of distribution at steady state
WHO	World Health Organization

## List of Tables

<b>Table 1:</b> Main components of Herba Thymi .....	6
<b>Table 2:</b> Pharmacokinetic data of total thymol absorption and elimination in human plasma after single oral administration .....	10
<b>Table 3:</b> Thymus vulgaris L. liquid extract efficacy studies .....	13

## List of Figures

<b>Figure 1:</b> Thymol plasma concentration.....	8
<b>Figure 2:</b> Cumulative renal excretion of thymol sulphate and thymol glucuronide.....	8
<b>Figure 3:</b> Time course of thymol concentration in plasma.....	9

## **2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods**

### **2.7.1.1 Background and Overview**

The purpose of this report is to support an application for marketing authorization of *THIOPECTOL THYM SANS SUCRE EDULCORE AU MALTITOL, 6.5 g/100 ml, sirop* with an abridged dossier as allowed under Article 16a(1) (traditional-use registration) of Directive 2001/83/EC: Thyme syrup has been on the market in the European Community for several decades.

The principal active components in *THIOPECTOL THYM SANS SUCRE EDULCORE AU MALTITOL, 6.5 g/100 ml, sirop* are thymol and carvacrol.

The efficacy of *Thymus vulgaris* L. liquid extract has been well-documented over many years of widespread traditional use.

### **2.7.1.2 Summary of Results of Individual Studies**

This medicinal product will be registered as a traditional herbal medicinal product as defined in Directive 2001/83/EC under Article 16a(1) (traditional-use registration) and as such this section is not applicable.

### **2.7.1.3 Comparison and Analyses of Results Across Studies**

Not applicable as no such studies were performed.